权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Phase II Trial of Metformin for Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction

二甲双胍治疗保留射血分数的心力衰竭肺动脉高压的 II 期试验

基本信息

批准号：
10460583
负责人：
MARC A SIMON
金额：
$ 57.67万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-05-01 至 2024-02-29
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10460583
关键词：
Accelerometer Activities of Daily Living Acute Adenosine Monophosphate Aging Animal Model Biopsy Blinded Blood Vessels Blood capillaries Cardiac Catheterization Procedures Cardiopulmonary Cardiopulmonary Physiology Categories Cell Proliferation Characteristics Chronic Clinical Data Clinical Trials Congestive Cross-Over Trials Data Deacetylase Disease EFRAC Exercise Exercise Test Failure Formulation Glucose Transporter Heart Heart Diseases Heart Hypertrophy Heart failure Heterogeneity High Prevalence Hypoxemia Inhalation Insulin Receptor Insulin Resistance Intervention Knowledge Lead Left Liver Lung Lung diseases Measures Mediating Metabolic Metabolic Control Metabolic hormone Metabolic syndrome Metabolism Metformin Mitochondria Monitor Morbidity - disease rate Muscle Fibers Nitrites Obesity Observational Study Oral Outcome Patients Phase Phase II Clinical Trials Phenotype Phosphorylation Physiological Physiology Placebos Process Protein Kinase Public Health Pulmonary Hypertension Pulmonary Wedge Pressure Pulmonary artery structure Reporting Resistance Respiratory Failure Role Serum Signal Transduction Sirtuins Skeletal Muscle Smooth Muscle Myocytes Testing Therapeutic Clinical Trial Time Treatment Failure Venous Venous Pressure level Walking Workload adipokines adiponectin aging population base chronic thromboembolic pulmonary hypertension clinical heterogeneity diabetic disorder risk fibroblast growth factor 21 glucose metabolism glucose tolerance glucose uptake hemodynamics high risk improved improved outcome insight insulin sensitivity lung pressure mortality novel patient population phase 2 study phase II trial platelet-derived growth factor BB pre-clinical preservation pressure primary outcome programs pulmonary arterial hypertension pulmonary arterial pressure secondary endpoint sensor targeted treatment translational clinical trial vascular abnormality

项目摘要

Heart failure with preserved ejection fraction (HFpEF) is a major driver of morbidity and mortality among the aging population and is a rapidly growing public health problem. However, there are no specific therapies for HFpEF and the negative results of a growing number of clinical trials are thought to be due, in large part, to substantial clinical heterogeneity of HFpEF. This has led to a call for deeper phenotyping to better target therapeutic clinical trials. One specific HFpEF phenotype with particularly poor outcomes is pulmonary hypertension (PH), which can result from chronic congestion of the pulmonary vasculature in HFpEF. Altered glucose metabolism has also been implicated in both HFpEF and PH, as well as specifically the PH-HFpEF phenotype. Our preliminary data on the cardiopulmonary physiology of PH-HFpEF from a recent phase II clinical trial suggests abnormal aging of the pulmonary vasculature with a steep decline in its compliance. We found that PH-HFpEF patients are typically in their 60's with a high prevalence of metabolic syndrome characteristics. Further, observational research suggests metformin may be associated with improved outcomes in heart failure. Additionally, we have studied the impact of metformin in an obese animal model of PH-HFpEF and shown a reduction in pulmonary pressures associated with increased 5' adenosine monophosphate-activated protein kinase (AMPK) phosphorylation. Increased AMKP was associated with a novel finding of upregulated sirtuin-3 (SIRT3) in skeletal muscle, but not in the lung or heart. AMPK regulates glucose uptake in skeletal muscle and is dysregulated in metabolic syndrome, heart failure, and PH. We have found decreased activation of SIRT3 in skeletal muscle biopsies from HFpEF patients and that skeletal muscle activation of SIRT3 drives secretion of the myokine, fibroblast growth factor 21 (FGF21). FGF21 inhibits pulmonary artery smooth muscle cell proliferation and confers systemic benefits on insulin resistance in an AMPK-dependent manner. These lines of evidence together suggest that metformin has significant promise for the specific treatment of PH-HFpEF. We propose a 12-week blinded cross over trial of metformin in PH-HFpEF to improve exercise hemodynamics, functional capacity, and glucose metabolism. This phase II clinical trial will provide detailed phenotyping and physiological data on PH-HFpEF (Aim 1). The primary outcome will be exercise mean pulmonary artery pressure. Secondary endpoints will include functional capacity as assessed by continuous work load exercise testing, activity monitoring by accelerometer, distance walked in 6 minutes, as well as cardiopulmonary hemodynamics (pulmonary artery pressures, resistance, and vascular compliance). Glucose tolerance and insulin sensitivity will be assessed. Skeletal muscle biopsies will be taken to study SIRT3-AMPK signaling, muscle fiber switch, and FGF21-adiponectin secretion (Aim 2). Results from this study will provide valuable insights into the cardiopulmonary and metabolic physiology of PH-HFpEF and may lead to novel and phenotypically specific therapy for this high-risk disease of aging.

心力衰竭伴保留射血分数（HFpEF）是糖尿病患者发病率和死亡率的主要驱动因素